Alnylam Pharmaceuticals and Quark Pharmaceuticals emerged as leading players  in this domain. It is worth mentioning that Alnylam Pharmaceuticals is a large ...

Recent approval of the RNAi based drug, Onpattro (developed by Alnylam Pharmaceuticals), for the treatment of hATTR amyloidosis has renewed the interest of ...

The RNA interference (RNAi) technique was discovered close to two decades ago. As of today, it is considered among the upcoming and versatile therapeutic ...